COMMUNIQUÉS West-GlobeNewswire

Medline Inc. announces closing of secondary offering of Class A common stock and full exercise of underwriters’ option to purchase additional shares
10/03/2026
NORTHFIELD, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that it has closed its secondary offering of 86,250,000 shares of Medline Inc.’s Class A common stock by [...]
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
10/03/2026
Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg IV cohorts; Received written FDA Type C meeting minutes; feedback is [...]
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
10/03/2026
DURHAM, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization, today announced the granting of an inducement award of restricted stock units (“ [...]
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
10/03/2026
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the [...]
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
10/03/2026
Initial clinical response data for AlloNK ® in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal trial design for AlloNK [...]
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
10/03/2026
Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026 Strengthened balance sheet provides [...]
TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results
10/03/2026
MALVERN, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum
10/03/2026
LEXINGTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to [...]
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum
10/03/2026
CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that [...]
Lifeward to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
10/03/2026
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of [...]
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2025 and Provides Business Update
10/03/2026
Generated TPOXX Product Revenues of $88 Million in 2025 Received $13 Million International Procurement Order for Oral TPOXX in January 2026 Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, March 10, 2026 ( [...]
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
10/03/2026
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in [...]
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
10/03/2026
NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers [...]
Philips connects patient monitoring and diagnostics to advance platform-based care intelligence at HIMSS26
10/03/2026
March 10, 2026 Amsterdam, the Netherlands, and Las Vegas, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today highlighted how open, interoperable, AI-enabled platforms can help health [...]
Orion Corporation: Managers’ transactions – Julia Macharey
10/03/2026
ORION CORPORATION MANAGERS’ TRANSACTIONS 10 MARCH 2026 at 17.00 EET Orion Corporation: Managers’ transactions – Julia Macharey Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) [...]
Orion Corporation: Managers’ transactions – Mikko Kemppainen
10/03/2026
ORION CORPORATION MANAGERS’ TRANSACTIONS 10 MARCH 2026 at 17.00 EET Orion Corporation: Managers’ transactions – Mikko Kemppainen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU [...]
Orion Corporation: Managers’ transactions – René Lindell
10/03/2026
ORION CORPORATION MANAGERS’ TRANSACTIONS 10 MARCH 2026 at 17.00 EET Orion Corporation: Managers’ transactions – René Lindell Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers’ transactions – Outi Vaarala
10/03/2026
ORION CORPORATION MANAGERS’ TRANSACTIONS 10 MARCH 2026 at 17.00 EET Orion Corporation: Managers’ transactions – Outi Vaarala Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers’ transactions – Hao Pan
10/03/2026
ORION CORPORATION MANAGERS’ TRANSACTIONS 10 MARCH 2026 at 17.00 EET Orion Corporation: Managers’ transactions – Hao Pan Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/ [...]

Pages